NSE: AJANTPHARM | BSE: 532331

Mid-range Performer

Download real time

2531.20 -13.70 (-0.54%)

26.16% Fall from 52W High

106.1K NSE+BSE Volume

NSE 24 Sep, 2025 3:31 PM (IST)

31,617.8

Market Cap

High in industry

0.7

Beta 1Year

Very Low volatility

Ajanta Pharma Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for AJANTPHARM, BSE:532331 Ajanta Pharma Ltd.

Ajanta Pharma Ltd.

05 Nov 2020

2531.20

-0.54%

Ajanta Pharma

Accumulate: Ajanta Pharma Ltd.

Dolat Capital

Ajanta Pharma reported stellar Q2 beating our estimates on the operating performance. Top-line grew 8% YoY, in-line with our estimate, driven by US and branded Africa business. Other geographies including India were muted. However, lower opex aided margins at 38.3% (up 490 bps QoQ and 1,070 bps YoY), way higher than our estimates. While the same is expected to taper as activities resume in subsequent quarters,...

Ajanta Pharma Ltd. is trading below all available SMAs

Ajanta Pharma Ltd.

04 Nov 2020

2531.20

-0.54%

Ajanta Pharma (BUY): Exceptional Q2 beat; H2 momentum to moderate

Buy: Ajanta Pharma Ltd.

Target

BOB Capital Markets Ltd.

Ajanta Pharma (AJP) posted Q2 revenue/EBITDA growth of 11%/54% YoY to Rs 7.2bn/Rs 2.7bn.

Ajanta Pharma Ltd. has an average target of 3022.00 from 6 brokers.

Ajanta Pharma Ltd.

21 Sep 2020

2531.20

-0.54%

Ajanta Pharma (BUY): NDR takeaways Earnings drivers tracking well

Buy: Ajanta Pharma Ltd.

Target

BOB Capital Markets Ltd.

We hosted investor meetings with the management of Ajanta Pharma (AJP).

Prabhudas Lilladhar released a report for Ajanta Pharma Ltd. on 19 Sep, 2025.

Ajanta Pharma Ltd.

31 Jul 2020

2531.20

-0.54%

US/Asia businesses drive superior performance

Buy: Ajanta Pharma Ltd.

Target

Motilal Oswal

EBITDA margin expanded at higher rate of 590bp YoY with superior product mix and controlled opex. We remain positive on AJP on its new launches, rising share in key markets of the US/India/Asia/Africa and improved operating leverage. Re-iterate In the branded formulation segment, AJP witnessed 15% YoY decline in India, while it delivered 27.8%/17.4% YoY growth in Asia/Africa in 1QFY21. AJP has strong pipeline of registration in both Asia/Africa branded segment. We expect Africa branded segment to deliver better 12% CAGR over FY20-22E to INR4.3b owing to increased offerings and better reach. AJPs US sales grew 46% YoY due to increased traction in existing With 19 ANDAs pending approval, the company has an intention to file 10-12 ANDAs annually. Considering 6-7 launches in FY21, we expect AJP to garner 20% CAGR in US sales over FY20-22E to INR7.3b in this segment.

Number of FII/FPI investors decreased from 385 to 371 in Jun 2025 qtr

Ajanta Pharma Ltd.

31 Jul 2020

2531.20

-0.54%

Ajanta Pharmaceuticals

Buy: Ajanta Pharma Ltd.

Target

ICICI Securities Limited

Domestic formulations - Focus on new launches, few therapies Domestic formulations comprise 30% of FY20 revenues. The main distinguishing factor is the uncanny knack of launching maximum number of first time launches with focus on new drug delivery system (NDDS). Out of 270+ actively marketed brands, ~60% were first time launches. However, a slowdown in dermatology segment due to increased competition in existing products and slow offtake in new launches are some near term challenges. We expect domestic formulations to grow at ~11% CAGR in...

Ajanta Pharma Ltd. has an average target of 3022.00 from 6 brokers.

Ajanta Pharma Ltd.

30 Jul 2020

2531.20

-0.54%

Ajanta Pharma (BUY): Solid beat on margins set to normalise in coming quarters

Buy: Ajanta Pharma Ltd.

Target

BOB Capital Markets Ltd.

Ajanta Pharma (AJP) posted Q1 revenue/EBITDA growth of 9%/33% YoY to Rs 6.7bn/Rs 2.2bn.

Ajanta Pharma Ltd. has an average target of 3022.00 from 6 brokers.

Ajanta Pharma Ltd.

22 May 2020

2531.20

-0.54%

Ajanta Pharmaceuticals

Buy: Ajanta Pharma Ltd.

Target

ICICI Securities Limited

Domestic formulations: Focus on new launches, few therapies Domestic formulations comprise 30% of FY20 revenues. Main distinguishing factor is the uncanny knack of launching maximum number of first time launches with focus on new drug delivery system (NDDS). Out of 270+ actively marketed brands, ~60% were first time launches. However, a slowdown in dermatology segment due to higher competition in existing products and slow offtake in new launches are some near term challenges. We expect domestic formulations to grow at ~12% CAGR in...

Ajanta Pharma Ltd. is trading below all available SMAs

Ajanta Pharma Ltd.

20 May 2020

2531.20

-0.54%

Ajanta Pharma (BUY): Near-term growth concerns but demand outlook intact

Buy: Ajanta Pharma Ltd.

BOB Capital Markets Ltd.

Ajanta Pharma (AJP) posted strong Q4 revenue/EBITDA growth of 32%/31% YoY to Rs 6.8bn/Rs 1.7bn.

Number of FII/FPI investors decreased from 385 to 371 in Jun 2025 qtr

Ajanta Pharma Ltd.

20 May 2020

2531.20

-0.54%

Earnings growth led by US/Asia and better operating leverage

Buy: Ajanta Pharma Ltd.

Target

Motilal Oswal

20 May 2020 Ajanta Pharma (AJP) ended FY20 on a healthy note with 15% earnings growth (v/s 12% compounded earnings decline over FY17-19), led by sales revival in Asia, Africa and new introductions in the US market. The companys major capex program would conclude in FY21 and only maintenance capex would be required FY22E onwards, indicating better free cash flow situation for AJP. We reduce our EPS estimate for FY21 by 6% to factor in the COVID-19 led slowdown in the branded generics segment. INR6.3b) grew 32% YoY, led by exports (+43%YoY; 74% of sales). Within exports, US generic sales were up 88% YoY (INR1.4b) and emerging markets sales grew 38% YoY (INR3b). Domestic formulation sales grew 11% YoY to INR1.8b (~26% of sales). Gross Margin (GM) came in at 74% and contracted 550bp YoY due to change in the product mix. AJP had forex loss of INR150m in other expenses. Adjusting for the same, EBITDA margin at 24.

Prabhudas Lilladhar released a report for Ajanta Pharma Ltd. on 19 Sep, 2025.

Ajanta Pharma Ltd.

20 Apr 2020

2531.20

-0.54%

Ajanta Pharmaceuticals

Buy: Ajanta Pharma Ltd.

Target

ICICI Securities Limited

On the business front, despite the nationwide lockdown, domestic growth is expected to remain more or less stable. Exports growth, barring for one or two months due to congestion in all major ports globally, is also expected to remain strong due to 1) currency benefit, 2) slowdown in competition due to delay in new approvals that will be beneficial for existing players and 3) expected demand continuum across the world despite Covid-19. Some windfall is also expected in some critical productsa case in point is Hydroxychloroquine, a malaria drug that is likely to be repurposed as a prophylaxis for Covid-19 treatment in some cases....

Promoters pledged 1.51% of shares in last quarter. Total pledge stands at 14.12% of promoter holdings

Is Ajanta Pharma Ltd. worth buying?

189 Votes:

Buy 77.25%

Sell 15.87%

Hold 6.88%

RESEARCH REPORTS

Buy SEE REPORTS >

pdf

Buy SEE REPORTS >

pdf